Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
- 387 Downloads
Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer. Nanoparticle albumin bound (nab) paclitaxel was developed to reduce toxicities from paclitaxel and improve its efficacy. Thirty patients with stage I–III HER2 positive breast cancer were treated in the neoadjuvant setting with lapatinib 1,000 mg/day and nab-paclitaxel 260 mg/m2 every 3 weeks for four cycles. The primary end point of the trial was clinical response rate (cRR) with secondary end points including pathologic complete response rate (pCR), tolerability of the combination, and marker response. The cRR was 82.8% (24 patients) with six (20.7%) patients having complete clinical response, 18 (62.1%) having partial clinical response, and five (17.2%) stable disease. A pCR was observed in five of the 28 patients (17.9%). The most frequent grade 2 toxicities were neuropathy in nine patients (30%), fatigue in seven patients (23.3%), rash in 11 patients (36.7%), and bone pain in 10 patients (33.3%). There was no significant drop in the left ventricular ejection fraction (LVEF). Of the tissue markers examined, we were not able to find a predictor of response. The combination of lapatinib and nab-paclitaxel was well tolerated and provided good efficacy in women with HER2 positive breast cancer. This combination offers an alternative non-anthracycline-containing regimen for women with HER2 positive breast cancer.
KeywordsLapatinib Nab-paclitaxel Breast cancer Neoadjuvant therapy HER2
This clinical trial (ClinicalTrials.gov ID NCT00331630) was conducted through the support of GlaxoSmithKline. Abraxis BioScience Inc. provided nab-paclitaxel. Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, where all staining was conducted, provided the necessary support.
- 4.Ibrahim NK, Page R, Guthrie T et al. (2002) Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter phase II studies. In: Am Soc Clin Oncol Annu Conf, Orlando, FL. Proceedings of the American Society of Clinical Oncology 21 (#209)Google Scholar
- 12.Anonymous. Common toxicity criteria of the national cancer institute for adverse events, version 3.0.10. 2010. 10-10-2010Google Scholar
- 16.Coudert BP, Largillier R, Arnould L et al (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25:2678–2684PubMedCrossRefGoogle Scholar
- 17.Pegram M, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized pase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol, 2007 Annual Meeting Proceedings 25(18S):4570Google Scholar
- 18.Han HS, Doliny P, Blaya S et al. (2007) Dose-dense docetaxel, carboplatinum and trastuzumab (ddTCH) as neoadjuvant therapy for human epidermal receptor 2 (HER2) positive breast cancer. ASCO. J Clin Oncol, 2007 Annual Meeting Proceedings 25(18S). 2010. ASCO. 2007Google Scholar
- 21.Untch M, Loibl S, Bishoff J et al (2010) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy. Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 70(Suppl 24):81sGoogle Scholar
- 22.Gianni L, Pienkowski T, Im Y-H et al (2010) Neoadjuvant pertuzumab and trastuzumab: antitumor and safety analysis of a randomized phase II study (neosphere). Cancer Res 70(Suppl 24):82sGoogle Scholar
- 23.Baselga J, Bradbury I, Eidtmann H et al (2010) First results of the NeoALTTO trial (BIG 01–06/EGF 106903): a phase III randomized open label neoadjuvant study of lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 70(Suppl 24):82sGoogle Scholar
- 24.Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384PubMedCrossRefGoogle Scholar